CCELHealthcare · Medical Care FacilitiesCCEL Stock Forecast: Cryo-Cell International, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 1 Aug 2026 — in the upper half.
CCEL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cryo-Cell International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Cryo-Cell International, Inc. — and when they’d sell — is the membership.
CCEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2025 | Maxim Group | Downgrade | Hold | — |
| 4 Mar 2025 | Maxim Group | Maintains | Buy | — |
| 29 Aug 2022 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CCEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cryo-Cell International, Inc. (CCEL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 475.0×
- Price / sales
- 0.9×
- Price / book
- −1.6×
- EV / EBITDA
- 38.3×
Cheaper than 2% of US stocks
Cheaper than 72% of US stocks
Cheaper than 95% of US stocks
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- −1.9%
- Earnings growth (YoY)
- 55.9%
- Gross margin
- 78.4%
- Operating margin
- 15.4%
- Net margin
- −7.9%
Higher than 26% of US stocks
Higher than 79% of US stocks
Higher than 90% of US stocks
Higher than 74% of US stocks
Higher than 21% of US stocks
- Return on equity
- 13.1%
- Return on assets
- −0.1%
- Dividend yield
- 17.5%
Higher than 71% of US stocks
Higher than 43% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CCEL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CCEL appears on the weeks it earns a place.
Frequently asked questions about CCEL stock
Is CCEL stock a buy right now?
Of the 1 analysts covering Cryo-Cell International, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cryo-Cell International, Inc. 72 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CCEL?
As at 1 Aug 2026, Cryo-Cell International, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
What is the CCEL stock forecast for 2030?
No analyst covering Cryo-Cell International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCEL are extrapolating price history, which says nothing about the business.
How has CCEL stock performed over the past year?
Cryo-Cell International, Inc. returned -29.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cryo-Cell International, Inc. do?
Cryo-Cell International Inc. is a prominent biotechnology company that specializes in cord blood and tissue banking services.
About Cryo-Cell International, Inc.
Cryo-Cell International Inc. is a prominent biotechnology company that specializes in cord blood and tissue banking services. Established with a focus on providing families with the opportunity to preserve vital biological resources, Cryo-Cell collects and stores umbilical cord blood and tissue at the time of a child's birth. These stored cells can potentially be used in future medical treatments due to their ability to differentiate into various cell types. The primary purpose of Cryo-Cell is to offer reliable and accessible solutions for parents wishing to safeguard their children's health against potential future illnesses, such as blood disorders and certain genetic diseases. Operating within the healthcare and biotech sectors, Cryo-Cell International Inc. plays a crucial role in the rapidly evolving field of regenerative medicine, contributing to advancements in cellular therapies and research. With its headquarters in Oldsmar, Florida, the company is a significant participant in the biotechnology industry, known for its emphasis on innovation, quality control, and adherence to rigorous industry standards. As a trusted entity in its domain, Cryo-Cell remains committed to expanding its scientific capabilities and enhancing the scope of its services, thereby impacting the broader medical and scientific communities.
CEO Mr. David I. Portnoy · 72 employees · United States · https://www.cryo-cell.com